Showing 2181-2190 of 2732 results for "".
- Galderma Establishes new US Headquarters in Florida to Strengthen Regional Leadershiphttps://modernaesthetics.com/news/galderma-establishes-new-us-headquarters-in-florida-to-strengthen-regional-leadership/2475385/Galderma announced Tuesday the company is establishing a new US headquarters in Miami, Florida. The new location aims to position Galderma at the heart of a thriving market for Dermatological Skincare and Injectable Aesthetics. The headquarter will be in the Brickell neighborhood
- SkinSpirit Shows Pride Month Support with $10,000 Donation to The Trevor Projecthttps://modernaesthetics.com/news/skinspirit-shows-pride-month-support-with-10000-donation-to-the-trevor-project/2475383/June kicked off Pride month in the United States and national medspa chain SkinSpirit is showing support through its philanthropic arm, SS Gives. SkinSpirit is donating $10,000 to The Trevor Project. “At SkinSpirit, one of our core values is leading with love,” Ly
- GALDA Co-Director Explains Organization's Work and Impacthttps://modernaesthetics.com/news/galda-co-director-explains-organizations-work-and-impact/2475382/The Gay and Lesbian Dermatology Association (GALDA) is an organization of dermatologists and health-care professionals dedicated to unity and networking of the gay community at dermatology meetings. For Pride Month, we spoke with GALDA co-director William L Waller III, MD, FAAD, to learn more abo
- Hydrafacial’s New HydraFillic with Pep9 Booster Targets Fine Line, Wrinkleshttps://modernaesthetics.com/news/hydrafacials-new-hydrafillic-with-pep9-booster-targets-fine-line-wrinkles/2475381/The Hydrafacial Company this week announced its latest innovation, the Hydrafacial HydraFillic with Pep9TM Booster. The HydraFillic with Pep9TM Booster is Hydrafacial’s first peptide-powered booster, formulated with a new proprietary complex of 9 peptides. It
- 2025 SCALE: Enhancing Injection Safety and Precision with Ultrasound Guidancehttps://modernaesthetics.com/news/2025-scale-enhancing-injection-safety-and-precision-with-ultrasound-guidance/2475379/At the 20th anniversary of Music City Symposium for Cosmetic Advances and Laser Education (SCALE), Benjamin Ascher, MD, gave a lecture titled “Why Injections Under Ultrasound Guide Are Crucial in Aesthetic Medicine.” Dr. Ascher explained shifts in facial injection practices,
- Dr. Sebastian Cotofana Shares Unpublished Research Targeting Glabellar Lines with Neurotoxins at SCALEhttps://modernaesthetics.com/news/dr-sebastian-cotofana-shares-unpublished-research-targeting-glabellar-lines-with-neurotoxins-at-scale/2475377/The 20th anniversary of Music City Symposium for Cosmetic Advances and Laser Education (SCALE) was held from May 14 to 18 at the Grand Hyatt in Nashville, Tennessee. The agenda included an update on neurotoxin related to facial anatomy for improved aesthetic outcomes from Seb
- 2025 SCALE: Temple Filler Is Underappreciated But Crucialhttps://modernaesthetics.com/news/2025-scale-temple-filler-is-underappreciated-but-crucial/2475375/At the 20th anniversary of the Music City Symposium for Cosmetic Advances and Laser Education (SCALE), Vince Bertucci, MD, FRCPC, gave a lecture titled “Temple Fillers: Revisiting Current Dogma.” Key takeaway messages from the lecture included: <
- New Collaboration Enhances Precision and Patient Engagement in Post-Weight-Loss Treatmentshttps://modernaesthetics.com/news/new-collaboration-enhances-precision-and-patient-engagement-in-post-weight-loss-treatments/2475376/MNML Aesthetics announced a partnership with ShapeScale to integrate 3D body imaging into its MNML Tone Method, a multi-modality body contouring protocol. The collaboration aims to enhance clinical precision and patient engagement in aesthetic practices, particularly in post-weight-loss body tran
- FDA Panel Urges Removal of Talc from Consumer Products Due to Cancer Linkhttps://modernaesthetics.com/news/fda-panel-urges-removal-of-talc-from-consumer-products-due-to-cancer-link/2475371/A U.S. Food and Drug Administration (FDA) advisory panel has reinforced longstanding concerns over the carcinogenic potential of talc, urging the agency to restrict its use in foods, drugs, and cosmetics.
- First Patient Dosed with GPX4 Modulator Targeting Pathologic Senescent Cellshttps://modernaesthetics.com/news/first-patient-dosed-with-gpx4-modulator-targeting-pathologic-senescent-cells/2475369/The first patient has been dosed with the lead drug candidate RLS-1496 in a single-center, ascending-dose, randomized, double-blind, vehicle-controlled trial, Rubedo Life Sciences, Inc., announced in a press release. The study marks the first time a glu